1	The effectiveness and safety of acupuncture kinesitherapy after					
2	percutaneous coronary intervention in patients with coronary heart					
3	disease: study protocol for a randomized controlled trial					
4						
5	Di Zhang ^{1#} , Huaimin Lu ^{2#} , Song Jin ^{1#} , Hong Guo ^{1#} , Xiaoxiao Liu ³ , Wensheng					
6	Xiao ² , Hongpeng Li ⁴ , and Jiang Ma ²					
7						
8	¹ Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu,					
9	Sichuan, China					
10	² Affiliated Sport Hospital Of Chengdu Sport University, Chengdu, Sichuan, China.					
11	³ Sichuan Integrative Medicine Hospital, Chengdu, Sichuan, China.					
12	⁴ Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, China.					
13	[#] Di Zhang, Huaimin Lu, Song Jin and Hong Guo are the co-first authors and					
14	contributed equally to the protocol. The author(s) declared no potential conflicts of					
15	interest.					
16	Corresponding author: Jiang Ma, Affiliated Sport Hospital Of Chengdu Sport					
17	University, No.251, Wuhouci Street, Wuhou district, Chengdu city, Sichuan province,					
18	China. E-mail: 2551864059@qq.com					
19						
20	Funding: This study is supported by the Science and Technology Development Fund					
21	of Hospital of Chengdu University of Traditional Chinese Medicine (Project					
22	No.20ZL02) and Sichuan Administration of Traditional Chinese Medicine (Project					
23	No.2020LC0081)					

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

24 Abstract

25 Background

Coronary heart disease(CHD) is a common disease of the cardiovascular system. 26 27 Percutaneous coronary intervention(PCI) has been proven an effective treatment. 28 Various complications after PCI may further affect the long-term efficacy of PCI. Previous trials have showed that both kinesitherapy(KT) and acupuncture are 29 beneficial to patients with CHD, but need further confirmation. Acupuncture 30 kinesitherapy(AKT) is a kind of combination therapy of acupuncture with exercise 31 32 training. In this study, we plan to conduct a randomized controlled trial(RCT) to confirm the superior efficacy of AKT compared to KT and conventional medical 33 therapy(MT) in post-PCI rehabilitation for CHD patients, and to further guide the 34 clinical strategy. 35

36 Methods

This is a single-center randomized controlled trial with 3 parallel arms. We will 37 recruit 102 CHD patients after PCI and randomly assign them to 3 groups. 38 Participants in 3 groups will receive 2-week MT. Besides, participants in AKT and 39 KT groups will also receive acupuncture kinesitherapy and kinesitherapy alone, 40 respectively. They will be treated once a day, 5-day a week, and the treatment course 41 will last for a total of 2-week with a 2-day off during the course. The primary 42 outcome is the changes in cardiac function. The secondary outcomes include aerobic 43 capacity, muscle strength, flexibility, balance, coordination, mental status, and 44 activity of daily living. All outcomes will be measured at baseline and 2-week after 45 treatment. Adverse events also will be recorded. The cardiac function and activities of 46 daily living will be followed up at 1, 3 and 6 months after treatment. 47

48 **Discussion**

49 We expect findings of trial will provide important insight into application of AKT as a

- 50 safety and more effective method for CHD patients. Successful completion of this
- 51 proposed study will also contribute to promotion of AKT in the clinic in the future.

52 Trial registration

53 Chinese clinical trial registry (Register Number: ChiCTR2100048960) http://www.

54 chictr.org.cn/index.aspx.

56 **1. Introduction**

57 Coronary heart disease (CHD), also known as coronary artery disease (CAD), is a common disease of the cardiovascular system, and also the main cause of death in 58 patients with cardiovascular disease [1]. The number of patients with cardiovascular 59 diseases in China reached 330 million, among which the number of CHD was 11 60 million, according to the summary of the China Cardiovascular Health and Disease 61 Report 2019 [2]. Percutaneous coronary intervention (PCI), a transcardiac catheter 62 technology which dredges stenosis or occlusion of the coronary artery lumen to 63 improve the blood perfusion of the myocardium, has been proven an effective 64 treatment to reduce mortality and morbidity in patients of CHD [3-6]. However, PCI 65 cannot reverse or slow down the process of coronary atherosclerosis and eliminate the 66 risk factor for CHD. Coronary artery stenosis or occlusion results in myocardial 67 ischemia, necrosis, and cardiac dysfunction, which further follows by various 68 complications after PCI, including acute coronary artery occlusion, coronary spasm, 69 coronary artery perforation, and even restenosis or thrombus, which may further 70 affect the long-term efficacy of PCI [7-9]. Medical therapy (MT) including tirofiban, 71 calcium antagonist and aspirin is usually applied for the treatment of complications 72 after PCI. However, the long-term medication accompanies with inevitable 73 gastrointestinal side effects such as bleeding, nausea, vomiting, etc., and cannot 74 continuously and effectively improve the prognosis after PCI [10-12]. 75

Kinesitherapy (KT), a central element of cardiac rehabilitation programs, is 76 recognized as integral to the comprehensive care and has been given a Class I 77 recommendation from the American Heart Association, the American College of 78 79 Cardiology, and the European Society of Cardiology [3,12-14]. Researches on the efficacy of KT for CHD patients after PCI are inconsistent. Several studies [15-20] 80 and systematic reviews [21] showed that KT can effectively improve cardiac and 81 vascular functions for patients after PCI, and reduce the morbidity of cardiovascular 82 events and the recurrence and mortality of CHD. The muscle strength, muscle 83 endurance, balance, coordination ability, and quality of life have also been improved 84 by KT, as well as the safety of KT [22-24]. However, two systematic reviews [25,26] 85 showed that KT had no significant effect on restenosis, recurrence of myocardial 86 infarction, improvement of cardiac function, and reduction of adverse cardiovascular 87 events in patients after PCI. 88

Acupuncture kinesitherapy (AKT) is a kind of moving acupuncture therapy with exercise training carried out following acupuncture. Ocular acupuncture, an acupuncture treatment manipulated on orbit with 8 areas and 13 acupoints, has been approved by the Standardization Administration of China in 2009 [27]. Doctor Jingshan Peng, the professor of Liaoning University of Traditional Chinese Medicine,

abstracted and summarized the theory of ocular acupuncture according to the Eight 94 Profile and Meridian theories of the Traditional Chinese Medicine in the early 1970s. 95 acupuncture around the orbital margin is recognized as a sort of micro-acupuncture, 96 which can activate the meridians, invigorate blood, relieve pain and regulate viscera 97 functions by stimulating acupoints around the orbital margin [28,29]. According to 98 the Meridian Theory of the Traditional Chinese Medicine [30,31], the tissue around 99 the eye is closely related to the Zang and Fu organs, and acupuncture around the eye 100 is effective in treating heart diseases. Mao [32] found that acupuncture on the 101 acupoints of the "Heart Area" and the "Upper Jiao Area" around the eye can 102 significantly reduce the time and frequency of angina pectoris in patients with CHD, 103 as well as the levels of TNF- α and CRP. 104

Studies show that the proportion of postoperative rehabilitation after PCI is about 60% in the United States, while it is still in its infancy in China [33,34]. Due to the frequent complications after PCI for CHD, it is imperative to carry out postoperative rehabilitation therapy after PCI in China. AKT may be an effective treatment for CHD patients after PCI. It is expected to optimize the post-PCI rehabilitation program by reducing complications after PCI, prolonging postoperative survival time, and improving the quality of life for CHD patients after PCI.

We plan to conduct a randomized controlled trial (RCT) to confirm the superior efficacy of AKT compared to KT and conventional medical therapy (MT) in post-PCI rehabilitation for patients of CHD. Changes in cardiac function, aerobic capacity, muscle strength, flexibility, balance, coordination, mental status, and activity of daily living will be measured to evaluate the efficacy of AKT comprehensively. Findings of this study are expected to provide an evidence-based decision on the application of AKT for CHD patients after PCI.

119 **2. Methods and Design**

120 2.1 Design

This is a single-center RCT with 3 parallel arms that aims to observe the effectiveness 121 and safety of AKT for post-PCI rehabilitation and to compare the effects of AKT, KT, 122 and MT. This trial has been approved by the Institutional Review Board of Hospital 123 124 of Chengdu University of Traditional Chinese Medicine in July 2021 (reference number: 2021KL-028) and been registered (ChiCTR2100048960) at the Chinese 125 Clinical Trial Registry in July 2021. The trial will be conducted in the Hospital of 126 Chengdu University of Traditional Chinese Medicine. The whole study period is a 127 2-week intervention phase. After stratified randomization, participants in 3 groups 128 will receive 2-week MT. Besides, participants in AKT and KT group will also receive 129 acupuncture kinesitherapy and kinesitherapy alone, respectively. They will be treated 130

once a day, 5 days a week, and the treatment course will last for a total of 2 weeks with a 2-day off during the course. Outcomes will be measured at baseline and 2 weeks after intervention, the cardiac function and activities of daily living will be followed up at 1, 3 and 6 months after treatment. All participants will be required to sign the written informed consent before randomization. The flow diagram of this trial is presented in **Fig. 1**. To provide a high quality of evidence, we will conduct this trial in line with Standard Protocol Items: Recommendations for Interventional Trials

138 (SPIRIT) [35] and report our findings in accordance with the Consolidated Standards

139 of Reporting Trial (CONSORT) statement [36].

140 **2.2 Participants**

141 **2.2.1 Diagnostic criteria**

- 142 Patients conform to the diagnostic criteria of the 2016 American College Of
- 143 Cardiology / American Heart Association Guideline Focused Update on Duration of
- 144 Dual Antiplatelet Therapy in Patients With Coronary Artery Disease [37] can be
- 145 recruited, the diagnostic criteria are shown following:
- 146 (1) The patient had a history of CHD with angina pectoris.
- 147 (2) Changes in ECG
- 148 ① stable angina pectoris: ECG is almost in the normal range during the remission
- 149 period. During the attack of angina pectoris, the ST-segment depression dominated
- by R-wave and T-wave is flat or inverted (ST-segment elevation in the lead of
- variant angina pectoris), which gradually recovers within a few minutes after theattack.
- 153 ② ST-segment elevation myocardial infarction: The ST-segment arched upward
- 154 (unidirectional curve) with or without pathological Q and R wave reduction
- 155 (ST-segment changes are not obvious in posterior wall myocardial infarction) in
- the early time. The hyperacute phase may be characterized by unusually tall and
- 157 two asymmetric T waves.
- 158 ③ Non-ST-segment lifting myocardial infarction: the ST-segment depression and
- 159 T wave inversion present dynamic changes. The T wave inversion gradually
- 160 deepens and then becomes shallower, and some abnormal Q waves appeared.
- 161 (3) For patients with myocardial necrosis, the concentrations of serum myocardial
- 162 markers, such as cTn, myoglobin, CK, and CK-MB are abnormally increased.
- (4) Coronary angiography shows that the stenosis of the coronary artery is more than50%.
- 165

166

167 2.2.2 Inclusion criteria

- Patients who fulfill all the following inclusion criteria will be included in this
- 169 study(**Table 1**).

Table 1. Inclusion criteria								
(1)CHD patients after PCI who were diagnosed with stable angina pectoris, NSTEMI,								
or STEMI.								
(2) Patients of medium and low risk stratification of post-PCI rehabilitation.								
Low risk	Middle risk							
① no angina pectoris or ECG changes	1 no angina or myocardial ischemia during							
during exercise or convalescence	moderate exercise or convalescence							
2 no arrhythmia in rest or exercise	2 no complicated ventricular arrhythmia							
	during rest or exercise							
³ no complications after thrombolytic	③no complication of cardiogenic shock or							
	heart failure after AMI, PCI, or CABG							
recanalization of AMI or CABG								
4no psychological disorders (depression,	(4) no severe psychological							
anxiety, etc.)	disorders(depression, anxiety, etc.)							
⑤LVEF≥50%	⑤40% <lvef<49%< td=""></lvef<49%<>							
⑥PVO≥20 [ml (min·kg)]	⑥15≤PVO≤19[mL (min·kg)]							
⑦predicted percentage of PVO≥80%	⑦65≤predicted percentage of PVO≤79%							
$(AT \ge 15[ml/(min \cdot kg)])$	$\otimes 12 \leq AT \leq 14 \ [ml/(min \cdot kg)$							
Inormal cTn	(9)normal cTn							
⁽¹⁰⁾ selective PCL single-vessel disease.	⁽¹⁾ emergency PCI, partial revascularization							
	PCL multiple vessel disease							
(3) $45 \le age \le 80$.	,							

(4) 24h after PCI with stable vital signs.

(5) Patient is willing to sign the informed consent form.

Abbreviations: ECG: electrocardiograph; LVEF: left ventricular ejection fraction; PVO: partial
venous oxygen pressure; AT: antithrombase; AMI: acute myocardial infarction; CABG: coronary
artery bypass grafting; cTn: troponin; NSTEMI: non-ST-segment elevation myocardial infarction;
STEMI: ST-segment elevation myocardial infarction

174

176 **2.2.3 Exclusion and withdrawal criteria**

177 Patients who meet one of the following criteria will be excluded and allowed or

- required to withdraw from the trial (**Table 2**). The reasons and exit time will be
- 179 recorded in standard case report forms (CRF).
- 180

Exclusion criteria	Withdrawal criteria			
(1) Patients with unstable vital signs.	(1) participants developing a serio disease which is not suitable to contin in the investigator's opinion.			
(2) Patients with serious complications such as malignancy, heart failure, respiratory failure, shock, etc.	(2) seriously adverse events happen.			
(3) Patients with cognitive impairment, severe hearing and visual impairment.	(3) participants request to withdraw from the trial.			
(4) Patients with severe liver, kidney, and immune dysfunction.				
(5) Pregnant women and lactating patients.				
(6) Patients cannot be treated with acupuncture.				

182

183 **2.2.4 Attendance and drop-outs**

The attendance of each participant will be checked and recorded in the case report form(CRF). Drop-outs from causes such as house moving, the onset of severe diseases, or other medical complications are unavoidable, all the details will be recorded in the CRF.

188

190 **2.2.5 Recruitment**

191 Participants will be recruited by posters, doctor's recommendations, the internet and 192 the WeChat in Chengdu city. If participants meet the study criteria, they will be 193 required to sign an informed consent form prior to the inclusion of the study.

194 2.3 Randomisation and allocation concealment

Included participants will be randomly assigned into 3 groups (AKT group, KT group, and MT group) with a 1:1:1 ratio. The randomization sequence will be created using R3.5.1 by an independent statistician. The information of random numbers, allocation and intervention will be packed in opaque envelopes, and will be concealed to screeners and outcome assessors. Eligible participants will be informed with the allocation results through phone call after opening envelopes in order.

201 **2.4 Blinding**

The single blind method will be conducted in this study according to the nature of acupuncture and exercise. Participants and researchers are impossible to be blinded to the group assignment. All the outcomes will be measured by the same independent experienced assessors who are blinded to the allocation. After completing the statistical analyses, the group assignment will be revealed by the project manager.

207 **2.5 Sample size**

According to a previous study [38], the mean difference and standard deviation of 208 ejection fraction (EF), an index of cardiac function, were 52.15 ± 1.91 , 57.56 ± 2.13 and 209 210 59.92±1.93 for CHD patients after PCI, when comparing the effectiveness of AKT compared with KT and MT control. The sample size was calculated using One-Way 211 analysis of variance, F-Tests by the G. Power software. A sample size of 93 212 participants is required to sufficiently detect a target effect size. Considering a 10% 213 214 drop-out rate, we intend to enroll a total of 102 participants, with 34 participants in 215 each group.

216 **2.6 Intervention**

All participants will be asked to treat with MT after the vital signs are stable. We will use CRF to record the intervention progress of participants in the AKT, KT, and MT groups. To monitor the progress, we will collect and analyze the session attendance as well as the self-reported diaries.

- 1. AKT group: according to the standard treatment of ocular acupuncture approved by
- the Standardization Administration of China in 2009 [27], the "Upper-Jiao Area"
- and the "Heart Area" will be selected and penetrated horizontally 2mm outside the
- orbital margin using the specially-made ocular acupuncture instrument. The ocular

acupuncture instrument will be kept embedding until the daily following KT is 225 completed. KT refers to experts consensus of exercise rehabilitation after PCI in 226 patients with CHD published by the Chinese Journal of Interventional Cardiology 227 in 2016 [39]. KT, including warm-up exercises (low levels of aerobic exercise), 228 exercise training(aerobic training, walking training, treadmill training, resistance 229 training, upper limb flexion adduction and abduction exercise, lower extremity 230 knee flexion and extension exercise, and flexibility training), and relaxation 231 training (stretching exercise), will be performed immediately based on the 232 conditions of patients after the acupuncture. It will be manipulated once a day, 5 233 days a week, and lasting for a total of 2 weeks with a 2-day off during the course. 234 We also will adjust the prescription of exercise according to the patient's sweating, 235 breathing, pulse and blood pressure. 236

237 2. KT group: the KT program will be the same as that in the AKT group.

238 3. MT group: MT refers to the Chinese Guidelines for PCI published by the Chinese

Journal of Cardiology in 2016 [40]. Aspirin enteric-coated tablets, Clopidogrel bisulfate tablets, and the Atorvastatin Calcium Tablets will be applied. Subjects will be asked to take aspirin enteric-coated tablets before (100~300mg) and after the PCI (100mg, QD, 2 weeks). Clopidogrel bisulfate tablets will be taken at least 6h before surgery (300~600mg), 2h~6h before surgery (600mg), and after the PCI (75mg, QD, weeks). Oral Atorvastatin Calcium Tablets will be administered 10mg/d for 2 weeks.

During the study, subjects will also be given antihypertensive and hypoglycemic drugs according to their complications. After the study, follow-up treatment will be conducted under the guidance of a professional cardiologist.

249 **2.7 Baseline assessment**

The participants will undergo baseline assessment before intervention. A descriptive exploratory questionnaire will be administered to collect information as follows:

- (1) Demographic and socioeconomic variables (height, weight, gender, age, marital
 status, education, history, family history, etc.);
- (2) Clinical variables (temperature, blood pressure, pulse respiration, liver function,
 kidney function, etc.);
- 256 (3) General characteristic variables (course of CHD; interventional duration of PCI;
- the location and extent of coronary artery lesions; complete revascularizations or not;
- 258 PCI-related complications or not; postoperative medications; rehabilitation plans;
- rehabilitation beginning time; treatment course, etc.)

261 **2.8 Outcome measurements**

262 **2.8.1 Primary outcome**

The primary outcome is the cardiac function between baseline and 2-week after treatment.

265 (1) 24h Holter Electrocardiogram. The 24-hour Holter electrocardiogram will be used

to record the 24h average/lowest/highest heart rate rhythm ST-T changes, heart rate

variability (HRV, SDA, HF, LF, LF/HF) and other indicators of the subjects to evaluate the arrhythmias in PCI myocardial ischemia and changes in autonomic nerve function.

- 270 (2) Color Doppler Echocardiography. The systolic and diastolic functions of the
- subjects will be evaluated by using doppler echocardiography to record the SV, CO,
 FS, EF, IVRT, and E/A.
- 273 (3) Cardiac markers. Mb, cTn, CK, CK-MB α , TNF- α , hs-CRP, and BNP will be
- 274 detected by venous blood collection. IL-6 levels will be evaluated for ischemic
- 275 necrosis of heart injury

276 **2.8.2 Secondary outcomes**

277 Aerobic capacity (evaluated by 6min walking test), muscular strength (measured by manual muscle test and isokinetic strength), muscle flexibility (measured by Thomas 278 test), coordination (measured by finger nose test, finger-finger test and heel-knee shin 279 test), balance (measured by Berg Balance Scale), psychological states (measured by 280 self-rating anxiety scale and self-Rating depression scale), and activities of daily 281 living (measured by basic activities of daily living) will be considered as secondary 282 283 outcomes. The secondary outcomes will be evaluated at baseline and 2-week after 284 treatment.

285 **2.9 Follow up**

The cardiac function and activities of daily living will be followed up at 1, 3 and 6 months after treatment to observe the long-term efficacy.

288 2.10 Safety monitoring

Adverse events are defined as any unexpected or uncomfortable signs, symptoms, or diseases, including fainting needles, bending needles, stagnation needles, subcutaneous hematoma, skin lesions, muscle soreness, abnormal breathing, and recurrence rate of cardiac events. If any adverse events happen during the entire observation period, all the details will be recorded in the CRF. Data Monitoring Committee (DMC) consisted of statistician, assessor, and experts will discuss and determine the patient should continue or not once an adverse event occurs.

296 **2.11 Data collection and management**

- 297 All data will be collected and managed using the Research Electronic Data Capture
- 298 (REDCap) system [41]. The data will be entered into the REDCap Database by a
- 299 dependent researcher, then double-checked by a second researcher. The statistician
- 300 will review the database to ensure accurate data collection and correct data export
- 301 for future analyses. All data will either be kept in the Hospital of Chengdu University
- 302 of Traditional Chinese Medicine and be backed up in different network drives.

303 **2.12 Data analysis**

The statistical analysis will be carried out using SPSS statistical package (version 304 23.0). Data will be expressed as mean \pm standard deviations. All primary and 305 secondary analyses will be analyzed based on intention-to-treat. Missing data will be 306 filled by the Last Observation Carry Forward rules. Demographic characteristics and 307 other baseline values will be described using descriptive statistics. Baseline 308 characteristics of participants will be compared using the chi-square test for 309 enumeration data and one-way analysis of variance for continuous variables. 310 311 Differences between the groups will be calculated as mean differences or odds ratios alongside their 95% confidence intervals. Multiple comparisons between the groups 312 will be adjusted according to the Bonferroni correction method. All tests will be 313 314 two-sided, with the P value less than 0.05 deemed statistically significant.

315 **2.13 Patient and public involvement**

No patient has been involved in the design, conception and conduction of this trial.
Recruitment and data collection began in May 2022, all participants are expected to

complete the trial by December 2023.

319 2.14 Ethics and dissemination

This trial will be conducted according to the principles of the Declaration of Helsinki, which has been approved by the Institutional Review Board of Hospital of Chengdu University of Traditional Chinese Medicine in July 2021 (reference number: 2021KL-028). If there is any modification to the protocol which may impact the conduction of this study, the potential benefit of the patient or may affect patient safety.

We will draft a formal amendment to the ethical review committee for approval prior to implementation. This clinical trial is also registered with an identifier (ChiCTR2100048960) at the Chinese clinical trial registry in July 2021. Risks and benefits will be explained clearly to the participants, and they will be given enough time to ask questions and decide whether they will participate in this trial. The authors intend to publish the findings of the study in peer-reviewed journals.

332 **3. Discussion**

This study aims to conduct a randomized controlled trial (RCT) to confirm the superior efficacy of AKT compared to KT and conventional medical therapy (MT) in post-PCI rehabilitation for patients of CHD, and to further guide the clinical strategy.

The tissue around the eye is closely related to the Zang and Fu organs, and 336 acupuncture around the eye is effective in treating heart and heart diseases. According 337 to the Meridian Theory of the Traditional Chinese Medicine [30,31], the Hand 338 Shaoyin Meridian of Heart, the Hand Shaoyin Divergent Meridian, and the Hand 339 Shaoyin Collateral circulate from the heart and the root of the tongue up to and 340 341 around the eyes. It is said that the heart controls people's minds and spirits, once the mind is stable, people would sleep well. Therefore, acupuncture around the eyes was 342 confirmed effective in treating insomnia patients of heart-kidney imbalance type, 343 heart-spleen deficiency type, and deficiency of yin and excess of heat type [42-46]. 344 Moreover, acupuncture on the acupoints of the "Heart Area" and the "Upper Jiao 345 Area" around the eve can significantly reduce the time and frequency of angina 346 pectoris in patients with CHD, as well as the levels of TNF- α and CRP [32]. These 347 findings provide theoretical basis and clinical basis for the use of acupuncture therapy 348 in the rehabilitation of CHD patients after PCI. 349

We will conduct strict quality control to achieve high reliability and 350 reproducibility. We will consult experts to formulate the Standard Operating 351 Procedure (SOP) of this study. Researchers involved in this study will receive 352 theoretical and practical training of SOP in screening eligible participants, completing 353 the CRF, and assessing outcomes. To improve the baseline consistency of participants, 354 we will strictly follow the inclusion and exclusion criteria for participant enrollment. 355 In addition, researchers and outcome assessors will be separated during the study 356 period. Allocation of participants will be concealed to outcome assessors and data 357 analysts. All researchers will conduct this trial in accordance with SOP. A monthly 358 quality control assessment will be performed to ensure research quality. The DMC 359 will supervise the study. 360

In this study, we expect findings of trial will provide important insight into application of AKT as a safety and more effective method for CHD patients. Findings of this study are expected to provide an evidence-based decision on the application of AKT and to optimize the post-PCI rehabilitation program by reducing complications after PCI, prolonging postoperative survival time, and improving quality of life for CHD patients after PCI.

368 Data Availability

369 The data and materials are available upon request from the corresponding author.

370 Authors' contributions

- 371 Conceptualization: Di Zhang, Huaimin Lu, Song Jin, Hong Guo.
- 372 Funding acquisition: Di Zhang.
- 373 Investigation: Jiang Ma, Xiaoxiao Liu, Wensheng Xiao, Hongpeng Li.
- 374 Methodology: Jiang Ma, Di Zhang.
- 375 Project administration: Hongpeng Li.
- 376 Supervision: Song Jin, Hong Guo.
- 377 Writing original draft: Jiang Ma.
- 378 Writing review & editing: Di Zhang, Huaimin Lu, Song Jin, Hong Guo, Xiaoxiao
- 379 Liu, Wensheng Xiao, Hongpeng Li.

380 **References**

- Dalen JE, Alpert JS, Goldberg RJ, Weinstein RS. The epidemic of the 20(th) century: coronary
 heart disease. Am J Med. 2014 Sep;127(9):807-812.
 https://doi.org/10.1016/j.amjmed.2014.04.015 PMID: 24811552.
- Summary of China Cardiovascular Health and Disease Report in 2019. Chin Circ
 J.2020,35(09):833-854. https://doi.org/10.3969/j.issn.1000-3614.2021.06.001.
- Cheitlin M. A report of the American College of Cardiology/American Heart Association Task
 Force on Practice Guidelines (ACC/AHA/ASE Committee Update the 1997 Guidelines on the
 Clinical Application of Echocardiography). Circulation. 2003,108.
 https://doi.org/10.1161/01.CIR.0000073597.57414.A9 PMID: 12952829.
- 4. Garcia S, Abdullah S, Banerjee S, Brilakis ES. Chronic total occlusions: patient selection and
 overview of advanced techniques. Curr Cardiol Rep. 2013;15:334.
 https://doi.org/10.1007/s11886-012-0334-2 PMID: 23319014.
- 5. Pan Y, Tan Y, Li B, Li X. Efficacy of high-dose rosuvastatin preloading in patients undergoing
 percutaneous coronary intervention: a meta-analysis of fourteen randomized controlled trials.
 Lipids Health Dis. 2015 Aug 27;14(1):97. https://doi.org/10.1186/s12944-015-0095-1 PMID:
 26306625.
- 6. Herrmann, J. Peri-procedural myocardial injury: 2005 update. Eur Heart J. 2005,26:2493–519.
 https://doi.org/10.1093/eurheartj/ehi455 PMID: 16176941.
- 7. Kelly DJ, Gershlick T, Witzenbichler B, Guagliumi G, Fahy M, Dangas G, et al. Incidence and
 predictors of heart failure following percutaneous coronary intervention in ST-segment
 elevation myocardial infarction: the HORIZONS-AMI trial. Am Heart J. 2011;162:663-670.
- 402 https://doi.org/10.1016/j.ahj.2011.08.002 PMID: 21982658.

403 8. Ying Z, Ma XJ, Zhang H. Effect of Trimetazidine in Patients Undergoing Percutaneous
404 Coronary Intervention: A Meta-Analysis. PloS one. 2015,10(9):e0137775.
405 https://doi.org/https://doi.org/10.1371/journal.pone.0137775 PMID: 26367001.

- 406 9. Zhou X, Chen JC. Is treatment with trimetazidine beneficial in patients with chronic heart
 407 failure? Plos One. 2014,9(5):e94660. https://doi.org/10.1371/journal.pone.0094660 PMID:
 408 24797235.
- Lavie CJ, Arena R, Swift DL, Johannsen NM, Sui X, Lee DC, et al. Exercise and the
 Cardiovascular System: Clinical Science and Cardiovascular Outcomes. Equine Veterinary
 Journal. 2015,22(S9):5-6. https://doi.org/10.1161/CIRCRESAHA.117.305205 PMID:
 26139859.
- 413 11. Buttar HS, Li T, Ravi N. Prevention of cardiovascular diseases: Role of exercise, dietary
 414 interventions, obesity and smoking cessation. Experimental & Clinical Cardiology. 2005,
 415 10(4):229-249. PMID: 19641674.
- 416 12. Balady GJ, Ades PA, Bittner VA, Franklin BA, Gordon NF, Thomas RJ, et al. Referral,
 417 enrollment, and delivery of cardiac rehabilitation/secondary prevention programs at clinical
 418 centers and beyond: a presidential advisory from the American Heart Association.
 419 Circulation. 2011;124:2951–2960. https://doi.org/10.1161/CIR.0b013e31823b21e2 PMID:
 420 22082676.
- 13. Perk J, De Backer G, Gohlke H, Graham I, Reiner Z, Verschuren M, et al. European 421 422 guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth 423 Joint Task Force of the European Society of Cardiologyand Other Societies on 424 Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine 425 societies and by invited experts). Eur Heart J. 2012;33:1635-701. https://doi.org/10.1093/eurheartj/ehs092 PMID: 22555213. 426
- 427 14. Wenger NK, Froelicher ES, Smith LK, Ades PA, Berra K, Blumenthal JA, et al. Cardiac
 428 rehabilitation as secondary prevention. Agency for Health Care Policy and Research and
 429 National Heart, Lung, and Blood Institute. ClinPract Guide Quick Ref Guide Clin.
 430 1995;17:1–23. PMID: 8595435.
- 431 15. Shuichi T, Satoru S, Takeshi B, Hiroshi T, Naohiko A, Yoshio Y, et al. Predictors of left
 432 ventricular remodeling in patients with acute myocardial infarction participating in cardiac
 433 rehabilitation. Circ J. 2004 Mar;68(3): 214-9. https://doi.org/10.1253/circj.68.214 PMID:
 434 14993775.
- I6. Zheng H, Luo M, Shen Y, Ma Y, Kang W. Effects of 6 months exercise training on ventricular
 remodelling and autonomic tone in patients with acute myocardial infarction and
 percutaneous coronary intervention. J Rehabil Med. 2008;40(9):776-9.
 https://doi.org/10.2340/16501977-0254 PMID: 18843433.
- 439 17. Kim YJ, Shin YO, Bae JS, Lee JB, Ham JH, Son YJ, et al. Beneficial effects of cardiac
 440 rehabilitation and exercise after percutaneous coronary intervention on hsCRP and

441 inflammatory cytokines in CAD patients. Pflugers Arch. 2008;455(6):1081-8.
442 https://doi.org/10.1007/s00424-007-0356-6 PMID: 17906875.

- 18. Munk PS, Valborgland T, Butt N, Larsen AI. Response of growth differentiation factor-15 to
 percutaneous coronary intervention and regular exercise training. Scand Cardiovasc J.
 2011;45(1):27-32. https://doi.org/10.3109/14017431.2010.516368 PMID: 20836754.
- Hambrecht R, Adams V, Erbs S, Linke A, Kränkel N, Shu Y, et al. Regular physical activity
 improves endothelial function in patients with coronary artery disease by increasing
 phosphorylation of endothelial nitric oxide synthase. Circulation. 2003;107(25):3152-8.
 https://doi.org/10.1161/01.CIR.0000074229.93804.5C PMID: 12810615.
- 450 20. Meyer P, Gayda M, Normandin E, Guiraud T, Juneau M, Nigam A. High-intensity interval 451 training may reduce in-stent restenosis following percutaneous coronary intervention with stent implantation A randomized controlled trial evaluating the relationship to endothelial 452 453 function and J. inflammation. Am Heart 2009;158(5):734-41. 454 https://doi.org/10.1016/j.ahj.2009.12.018 PMID: 20211291.
- 455 21. Anderson L, Oldridge N, Thompson DR, Zwisler AD, Rees K, Martin N, et al. Exercise-Based
 456 Cardiac Rehabilitation for Coronary Heart Disease: Cochrane Systematic Review and
 457 Meta-Analysis. J Am Coll Cardiol. 2016;6767(1):1-12.
 458 https://doi.org/10.1016/j.jacc.2015.10.044 PMID: 26764059.
- 22. Soga Y, Yokoi H, Ando K, Shirai S, Sakai K, Kondo K, et al. Safety of early exercise training
 after elective coronary stenting in patients with stable coronary artery disease. Eur J
 Cardiovasc Prev Rehabil. 2010;17(2):230-4. https://doi.org/10.1097/HJR.0b013e3283359c4e
 PMID: 20051870.
- 23. Pavy B, Iliou MC, Meurin P, Tabet JY, Corone S. Safety of exercise training for cardiac
 patients: results of the French registry of complications during cardiac rehabilitation.
 Archives of Internal Medicine. 2006;166(21):2329-34.
 https://doi.org/10.1001/archinte.166.21.2329 PMID: 17130385.
- 467 24. Lavie CJ, Arena R, Franklin BA. Cardiac Rehabilitation and Healthy Life-Style Interventions:
 468 Rectifying Program Deficiencies to Improve Patient Outcomes. J Am Coll Cardiol.
 469 2016;67(1):13-5. https://doi.org/10.1016/j.jacc.2015.09.103 PMID: 26764060.
- 470 25. Yang X, Li Y, Ren X, Xiong X, Wu L, Li J, et al. Effects of exercise-based cardiac
 471 rehabilitation in patients after percutaneous coronary intervention: A meta-analysis of
 472 randomized controlled trials. Sci Rep. 2017;17(7):44789. https://doi.org/10.1038/srep44789
 473 PMID: 28303967.
- Zhang H, Chang R. Effects of Exercise after Percutaneous Coronary Intervention on Cardiac
 Function and Cardiovascular Adverse Events in Patients with Coronary Heart Disease:
 Systematic Review and Meta-Analysis. J Sports Sci Med. 2019;18(2):213-22. PMID:
 31191090
- 478 27. Standardization Administration of China, standardized manipulations of acupuncture and
 479 moxibustion- part 15: eye acupuncture .2009;21709(15):1-9.

28. Dale RA. The systems, holograms and theory of micro-acupuncture. American Journal of
Acupuncture. 1999;27(3-4):207. PMID: 10729973.

- 29. Chi Y, Barth J, Wang M, Robinson N, Li ZH, Liu JP. Eye acupuncture for pain conditions: a
 scoping review of clinical studies. BMC Complement Med Thera. 2021;21(1):101.
 https://doi.org/10.1186/s12906-021-03272-8 PMID: 33757500.
- 30. Zhang D, Zeng F, Yang J, Li ZJ. Overview of modern research on heart-brain relative theory.
 Journal of Sichuan of Traditional Chinese Medicine. 2014;32(05):179-81.
 https://doi.org/CNKI:SUN:SCZY.0.2014-05-090.
- 488 31. Li ZJ, Zeng F, Lan L. Using functional brain imaging technique to study central mechanism of
 489 acupuncture therapy for chronic stable angina in view of heart-brain correlation. Acupuncture
 490 Research. 2014;39(04):337-40.
- 491 32. Mao L, Zhang W, Liu GH. Effect of eye acupuncture therapy on angina pectoris of coronary
 492 heart disease and its effect on blood CRP and TNF-α. Chinese Journal of Traditional Chinese
 493 Medicine. 2020,38(09):30-3. https://doi.org/CNKI:SUN:ZYHS.0.2020-09-008.
- 494 33. Aragam KG, Dai D, Neely ML, Bhatt DL, Roe MT, Rumsfeld JS, et al. Gaps in referral to
 495 cardiac rehabilitation of patients undergoing percutaneous coronary intervention in the
 496 United States. J Am Coll Cardiol. 2015;65(19):2079-88.
 497 https://doi.org/10.1016/j.jacc.2015.02.063 PMID: 25975470.
- 498 34. Chen JY, Chen YD, Han YL. Consensus of exercise rehabilitation experts after percutaneous
 499 coronary intervention. Chinese Journal of Interventional Cardiology. 2016;24(07): 361-9.
 500 https://doi.org/CNKI:SUN:ZJXB.0.2016-07-001.
- 501 35. Chan AW, Tetzlaff JM, Gøtzsche PC, Altman DG, Mann H, Berlin JA, et al. SPIRIT 2013
 502 explanation and elaboration: guidance for protocols of clinical trials. BMJ. 2013;346:e7586.
 503 https://doi.org/10.1136/bmj.e7586 PMID: 23303884.
- Schulz KF, Altman DG, Moher D. CONSORT 2010 Statement: updated guidelines for
 reporting parallel group randomised trials. BMC Med. 2010;8(1):18.
 https://doi.org/10.4103/0976-500X.72352 PMID: 21350618.
- 37. Levine GN, Bates ER, Bittl JA, Brindis RG, Fihn SD, Fleisher LA, et al. 2016 ACC/AHA
 Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With
 Coronary Artery Disease. Circulation. 2016;134(10):e123-155.
 https://doi.org/10.1016/j.jtcvs.2016.07.044 PMID: 27751237.
- 38. Wang XF, Gao YG and Zhang TS. Effects of exercise rehabilitation combined with
 psychotherapy in elderly patients with coronary heart disease after percutaneous coronary
 intervention. Chin J Geriatr. 2020;39(5):514-7.
 https://doi.org/10.3760/cma.j.issn.0254-9026.2020.05.007.
- S15 39. Chen JY, Chen YD, Han YL. Expert Consensus of exercise rehabilitation after percutaneous
 S16 coronary intervention. Chin J of Interventional Cardiol. 2016,24(07):361-9.
 S17 https://doi.org/CNKI:SUN:ZJXB.0.2016-07-001.

40. Han YL. Chinese guidelines for percutaneous coronary intervention. Chin J Cardiol.
2016;44(05):382-400. https://10.3969/j.issn.1000-3614.2016.ZK.003.

- 41. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data
 capture (REDCap)—a metadata-driven methodology and workflow process for providing
 translational research informatics support. J Biomed Inform. 2009;42(2):377–81.
 https://doi.org/10.1016/j.jbi.2008.08.010 PMID: 18929686.
- 42. Liu Y, Hai Y. A comparative observation of ocular acupuncture therapy in the treatment of
 cardiorenal incompatibility insomnia. Journal of Practical Traditional Chinese Internal
 Medicine. 2013,27(01):136-7. https://doi.org/CNKI:SUN:SYZY.0.2013-01-073
- 43. Li YT, Wang PQ. Clinical observation of ocular acupuncture therapy in treating 42 cases of
 heart-kidney imbalance type insomnia. Hunan J Tradit Chin Med. 2019,35(02):69-71.
 https://doi.org/CNKI:SUN:HNZO.0.2019-02-105.
- 44. Cheng X. Observation of clinical effect and mechanism of eye acupuncture combined with
 Gupi Decoction in treating insomnia of heart-spleen deficiency type. Liaoning University of
 Traditional Chinese Medicine. 2014.
- 45. Ma LN. Observation on the clinical effect of eye acupuncture on insomnia of heart-spleen
 deficiency type. Liaoning University of Traditional Chinese Medicine. 2016.
- 46. Wang DX. Observation on the curative effect of eye acupuncture therapy combined with
 Tianwang Buxin Dan in treating insomnia of deficiency of yin and excess of heat type.
 Liaoning University of Traditional Chinese Medicine. 2018.



Fig 2. CONSORT flow diagram

Figure 2

		STUDY PERIOD					
		Enrolment	Allocation		Post-allocation		
	TIMEPOINT	t _o	0	t1	t ₂	t3	t4
	ENROLMENT:						
	Eligibility screen	Х					
	Informed consent	х					
	Allocation		х				
	INTERVENTIONS:						
medRxiv prepr (which was	Acupuncture kinesitherapy int doi: https://doi.org/10.1101/2022.07.10.22277479; this ve not certified by peer review, is the author/funder, who has ut is made available under a CC-BY	rsion posted July 12, 2022 granted medRxiv a license 4.0 International license .	. The copy right holder for to display the preprint in	this preprint			
	Kinesitherapy (KT)		←				
	Medical therapy (MT)						
	ASSESSMENTS:						
	Demographic and						
	socioeconomic variables;						
	Clinical variables; General	х					
	characteristic variables						
	Aerobic capacity; muscular						
	strength; muscle flexibility;						
	coordination; balance;	×					
	psychological states;			×			
	psychological states						
	Cardiac function; activities						
	of daily living	X		X	Х	X	X

Fig 1. SPIRIT schedule of enrolment, interventions, and assessments.

Figure 1